Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia

Ann Hematol. 2023 Apr;102(4):973-975. doi: 10.1007/s00277-023-05110-y. Epub 2023 Feb 6.

Tongtong Zhang^{1

2}, Haixia Zhou^{1

2}, Mingzhu Xu^{1

2}, Chongsheng Qian^{1

2}, Aining Sun^{1

2}, Depei Wu^{1

2}, Shengli Xue^{3

4}

¹ Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China.
² Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215000, China.
³ Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215000, China. slxue@suda.edu.cn.
⁴ Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215000, China. slxue@suda.edu.cn.

No abstract available

Publication types